Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
BEVERLY, Mass. and TORONTO, Ontario, Aug. 16, 2017 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its financial results for the three and six months ended June 30, 2017 before the market opens on Tuesday, August 22, 2017. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.com and on www.sedar.com.
The Company will follow with a conference call Tuesday, August 22, 2017, at 11:00 a.m. EDT to review highlights of its quarterly results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 72072012. A recording of the call will be available on Hamilton Thorne’s website no later than five business days after the call.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact: David Wolf, President & CEO Hamilton Thorne Ltd. 978-921-2050 [email protected] Michael Bruns, CFO Hamilton Thorne Ltd 978-921-2050 [email protected]
